225Ac-DOTATATE is the alpha-labeled analogue of 90Y- and 177Lu-DOTATATE. Several academic centers are presently exploring this molecule with interesting results and it is not excluded that companies may soon be involved in pushing further the development of this drug. This alpha-labeled analogue of a radiolabeled somatostatin was developed to be used in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET) refractory to previous treatment with 177Lu-DOTATATE.
Target/Mechanism: Somatostatin receptors
Radiation Type: alpha particle (α)